Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
IgA nephropathy gains five approved drugs in four years

IgA nephropathy gains five approved drugs in four years

New Capabilities

Next-generation candidates now aim for longer dosing intervals and deeper disease control

June 1st, 2026: Jade Biosciences reports JADE101 Phase 1 results

Overview

For decades, doctors had no drugs specifically approved for IgA nephropathy, a kidney disease that pushes up to half of patients toward kidney failure within ten years of diagnosis. Since December 2021, the FDA has approved five.

The latest entrant in the pipeline aims to stretch dosing intervals. On June 1, Jade Biosciences reported early data from healthy volunteers: its experimental antibody JADE101 cut disease-driving IgA antibodies by about 70% after a single shot—and the effect lasted 12 weeks. If it works, that's four shots yearly, not monthly or daily.

Why it matters

About half of IgA nephropathy patients face kidney failure within a decade of diagnosis. Each new therapy changes that arithmetic for a young patient population.

Questions about this story

0

How does it work?

IgA nephropathy is driven by abnormal antibodies that lodge in the kidney; JADE101 blocks the protein (APRIL) that tells immune cells to make those antibodies, cutting their production by ~70% after a single shot.

Why it matters: Interrupting the disease earlier in the chain — before the abnormal IgA is even made — is a fundamentally different bet than the older approved drugs, which mostly reduce kidney pressure downstream.

  • The disease follows a 'four-hit' cascade: immune cells overproduce galactose-deficient IgA1 (an abnormal antibody), autoantibodies form immune complexes with it, those complexes deposit in the kidney's mesangium, and inflammation erodes kidney function over years.
  • APRIL (A Proliferation-Inducing Ligand) is the cytokine that drives B-cells to produce and class-switch toward pathogenic IgA1; blocking it upstream stops the cascade at its source — JADE101 binds APRIL with ultra-high affinity to do exactly that.
  • Jade engineered JADE101 for half-life extension, giving it a serum half-life of ~27 days; that's why a single dose suppresses IgA for 12 weeks, versus monthly dosing for Otsuka's sibeprenlimab (Voyxact), which shares the same APRIL-blocking mechanism.
  • The other four approved drugs act on downstream effects: budesonide (Tarpeyo) reduces mucosal IgA at gut lymph nodes, sparsentan (Filspari) and atrasentan (Vanrafia) cut kidney pressure via receptor blockade, and iptacopan (Fabhalta) blocks the complement system that amplifies kidney inflammation.
Sources
Jade Biosciences Phase 1 press release BAFF/APRIL in IgAN — Frontiers in Nephrology IgAN pathogenesis & treatment — Cleveland Clinic Journal of Medicine
Room for disagreement
  • Jade claims a 'best-in-class' edge over Voyxact (sibeprenlimab) based on tighter APRIL binding and longer half-life — but sibeprenlimab has actual patient trial data (VISIONARY: 54% proteinuria reduction) while JADE101's 70% IgA cut comes only from healthy volunteers, where the pathological milieu driving IgA overproduction is absent. Critics would note healthy-volunteer pharmacodynamics don't guarantee equivalent suppression in diseased patients.
AI-generated with web search — may be wrong. Check the linked sources.
Play on this story Voices Debate Predict Higher or Lower

Key Indicators

5
Approved IgAN drugs since 2021
Tarpeyo, Filspari, Fabhalta, Vanrafia and Voyxact have reached the U.S. market.
~70%
IgA reduction at 12 weeks (JADE101)
Single-dose Phase 1 result in healthy volunteers, sustained out to three months.
12 weeks
Dosing interval JADE101 is targeting
Most approved IgAN therapies are taken daily or dosed every four weeks.
~50%
Patients reaching kidney failure within 10 years
Disease typically appears in patients aged 34–45, creating a long horizon of dialysis or transplant risk.
2.5
Annual cases per 100,000 adults
Global incidence, with prevalence highest in Asia and lowest in Africa.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 4 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Higher or Lower Two numbers from this story. Guess which is bigger. 5 rounds to set a streak. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Tom Frohlich
Tom Frohlich
Leading JADE101 through Phase 2 with Phase 3 planned for 1H 2027

Organizations Involved

Jade Biosciences
Jade Biosciences
Public biotech (Nasdaq: JBIO)
Developing JADE101 for IgA nephropathy, Phase 2 underway

A clinical-stage antibody developer focused on autoimmune kidney disease.
Otsuka Pharmaceutical
Otsuka Pharmaceutical
Pharmaceutical company
Markets Voyxact, the first FDA-approved APRIL inhibitor for IgAN

Otsuka acquired Visterra and inherited sibeprenlimab, which became Voyxact.
Novartis
Novartis
Pharmaceutical company
Markets Fabhalta and Vanrafia for IgA nephropathy

Holds two approved IgAN drugs with different mechanisms.

Timeline

December 2021 June 2026

7 events Latest: June 1st, 2026 · 1 month ago
Tap a bar to jump to that date

  1. Jade Biosciences reports JADE101 Phase 1 results

    Latest Clinical Data

    Interim healthy-volunteer data show about 70% IgA reduction sustained at 12 weeks after a single dose, supporting a quarterly dosing schedule.

  2. Voyxact becomes first APRIL inhibitor approved for IgAN

    Regulatory

    Otsuka's sibeprenlimab is approved after the VISIONARY trial shows a 54% proteinuria cut.

  3. Vanrafia (atrasentan) approved for IgAN

    Regulatory

    Novartis's selective endothelin A receptor antagonist becomes the fourth FDA-approved option.

  4. Filspari converted to full approval

    Regulatory

    Two-year PROTECT data show sparsentan slows kidney function decline, supporting full approval.

  5. Fabhalta approved as first complement inhibitor for IgAN

    Regulatory

    Novartis's iptacopan, an oral complement factor B inhibitor, gains accelerated approval.

  6. Filspari (sparsentan) wins accelerated approval

    Regulatory

    Travere's dual endothelin/angiotensin receptor blocker is approved on proteinuria reduction.

  7. Tarpeyo becomes first FDA-approved IgAN drug

    Regulatory

    Calliditas wins accelerated approval for budesonide delayed-release, the first therapy specifically labeled for IgA nephropathy.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

December 2013 – October 2014

Hepatitis C direct-acting antivirals (2013–2014)

Gilead launched Sovaldi in December 2013 and Harvoni in October 2014, replacing year-long interferon-ribavirin regimens that cured roughly half of patients and caused severe side effects. The new pills cured more than 95% of patients in 8 to 12 weeks.

Then

Cure rates jumped above 95% and treatment durations collapsed from 48 weeks to 8–12 weeks. Gilead booked more than $19 billion in hepatitis C sales in 2015 alone.

Now

By 2026, the World Health Organization counts hepatitis C as a potentially eliminable disease, with new infections falling sharply in countries that funded broad treatment.

Why this matters now

Like IgA nephropathy today, hepatitis C went from one tolerable but unsatisfying regimen to a wave of differentiated competitors in a few years. The winners were the drugs that improved dosing convenience and depth of effect, not just the first approvals.

January 2021

HIV long-acting injectables (2021)

The FDA approved Cabenuva (cabotegravir plus rilpivirine) in January 2021 as the first long-acting injectable HIV regimen, replacing daily pills with monthly and later every-two-month shots. ViiV Healthcare and Janssen co-developed the drug.

Then

Patients who struggled with daily adherence switched to injections. Uptake was slowed by cold-chain logistics and clinic infrastructure requirements.

Now

Long-acting dosing became the explicit design target for the next generation of HIV drugs, including the every-six-month lenacapavir approved for prevention in 2025.

Why this matters now

JADE101's quarterly dosing pitch mirrors the HIV playbook: once you have effective therapies, the next axis of competition is how often patients have to think about the disease. The HIV case also shows that dosing convenience does not automatically translate into market dominance.

January 2012 – October 2019

Cystic fibrosis correctors (2012–2019)

Vertex Pharmaceuticals launched Kalydeco in 2012 and a series of follow-on combinations culminating in Trikafta in October 2019, which addresses the underlying CFTR protein defect in about 90% of cystic fibrosis patients.

Then

Median predicted survival for U.S. cystic fibrosis patients rose past 50 years, and lung function gains were measurable within weeks of starting Trikafta.

Now

Cystic fibrosis shifted from a pediatric-mortality disease to a chronic condition. Vertex captured almost the entire market and made cystic fibrosis the bulk of its revenue.

Why this matters now

Cystic fibrosis shows what happens when one company stacks improving products in a rare disease: a single firm can capture the category. For IgA nephropathy, the equivalent question is whether one of the current pipeline companies will assemble that kind of franchise, or whether the market stays fragmented.

Sources

(7)
+1
GlobeNewswire Jade Biosciences StockTitan TrialFriend Medscape Seminars in Nephrology Jade Biosciences